Novo Nordisk A/S (NYSE:NVO) Position Trimmed by Harbour Investment Management LLC

Harbour Investment Management LLC cut its stake in Novo Nordisk A/S (NYSE:NVO) by 0.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,911 shares of the company’s stock after selling 640 shares during the quarter. Novo Nordisk A/S makes up approximately 3.2% of Harbour Investment Management LLC’s portfolio, making the stock its 5th largest holding. Harbour Investment Management LLC’s holdings in Novo Nordisk A/S were worth $7,218,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Clearstead Trust LLC lifted its stake in Novo Nordisk A/S by 177.9% in the 4th quarter. Clearstead Trust LLC now owns 3,277 shares of the company’s stock valued at $282,000 after buying an additional 2,098 shares in the last quarter. Copperwynd Financial LLC lifted its stake in Novo Nordisk A/S by 8.8% in the 4th quarter. Copperwynd Financial LLC now owns 8,068 shares of the company’s stock worth $694,000 after purchasing an additional 650 shares in the last quarter. Ironwood Investment Management LLC lifted its stake in Novo Nordisk A/S by 0.9% in the 4th quarter. Ironwood Investment Management LLC now owns 19,912 shares of the company’s stock worth $1,713,000 after purchasing an additional 176 shares in the last quarter. Zevin Asset Management LLC lifted its stake in Novo Nordisk A/S by 47.0% in the 4th quarter. Zevin Asset Management LLC now owns 60,708 shares of the company’s stock worth $5,222,000 after purchasing an additional 19,416 shares in the last quarter. Finally, First National Trust Co lifted its stake in Novo Nordisk A/S by 12.9% in the 4th quarter. First National Trust Co now owns 2,954 shares of the company’s stock worth $254,000 after purchasing an additional 338 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of research reports. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Thursday. Finally, Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Three research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Up 1.8 %

Novo Nordisk A/S stock opened at $77.22 on Friday. Novo Nordisk A/S has a fifty-two week low of $73.80 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The firm has a 50 day moving average price of $83.95 and a 200 day moving average price of $103.24. The company has a market capitalization of $346.54 billion, a PE ratio of 23.47, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.